USA flag logo/image

An Official Website of the United States Government

BLOOD TISSUE IRON DEPLETION BY EXTRACORPOREAL CHELATOR

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16544
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16544
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Hemex Inc.
143 Windsor Ave. Buffalo, NY 14209
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: BLOOD TISSUE IRON DEPLETION BY EXTRACORPOREAL CHELATOR
Agency: HHS
Contract: N/A
Award Amount: $45,000.00
 

Abstract:

THE PRINCIPAL AIM OF THIS PHASE I GRANT IS TO DEVELOP A DEVICE WITH IMMOBILIZED CHELATOR OF CLINICAL CAPACITY, FOR REMOVAL OF EXCESS IRON FROM PATIENTS WITH IRON OVERLOAD. WE HAVE DEVELOPED SUCH A DEVICE, USING POLYSULFON HOLLOW FIBER CARTRIDGES WITH IMMOBILIZED CHELATORS, FOR ALUMINUM CHELATION IN DIALYSIS PATIENTS. PRELIMINARY STUDIES USING THIS CHELATING DEVICE INDICATE THAT IRON REMOVAL BY SUCH METHODOLOGY IS FEASIBLE. OTHER PRELIMINARY STUDIES DONE IN DOGS USING CARTRIDGES WITH IMMOBILIZED DESFERRIOXAMINE SHOWED THAT IRON COULD BE REMOVED RAPIDLY BY SUCH TECHNIQUES. IN PHASE I, WE PLAN TO DEVELOP SEVERAL TYPES OF IMMOBILIZED CHELATORS. USING ACTIVATED AGAROSE AS A MACROMOLECULAR SUPPORT, WE WILL IMMOBILIZE SOME NEW ORAL CHELATORS (EHPG, PIH) AND ALPHA-AMINOACYL HYDROXAMATE, A CHELATOR LIGAND WITH HIGH IRON AFFINITY. WE WILL PREPARE A SERIES OF CARBOXYMETHYL-DEXTRANS WITH INCREASE CONTENT OF ACID GROPUS FOR THE BINDING OF LARGE AMOUNTS OF THE DESFERRIOXAMINE FOR IRON CHELATORS. WE WILL THEN MEASURE IRON BINDING CAPACITY OF EACH OF THE ABOVE CHELATING AGENTS IN BATCH EXPERIMENTS. IRON DEPLETION BY EACH OF THE CHELATORS WILL BE MEASURED USING SALINE SOLUTION WITH ALBUMIN WHICH CONTAINS VARIOUS CONCENTRATIONS OF IRON, BETWEEN 50 AND 500 MCG/DL. THE STRENGTH OF IRON BINDING WILL BE ESTIMATED BY THE ELUTED AMOUNT OF IRON BY WATER SOLUBLE CHELATORS, SUCH AS EDTA. CHELATORS THAT LOOK PROMISING IN THE BATCH EXPERIMENTS WILL BE IMMOBILIZED ONTO HOLLOW FIBER CARTRIDGES. CARTRIDGES FOR IMMOBILIZATION WILL BE THOSE MARKED FOR HEMODIALYSIS WITH HIGH ULTRAFILTRATION PERFORMANCE. EACH CARTRIDGE CONTAINS ABOUT 12,000, ASYMMETRIC POLY-SULFON HOLLOW FIBERS CONSISTING OF A THIN CAPILLARY MEMBRANE SURROUNDED BY A RELATIVE THICK, MACROPOROUS SHELL WHICH IMPARTS MECHANICAL STRENGTH TO THE MEMBRANE AND SERVES AS A SUPPORT TO THE CHELATING AGENT WHICH IS DEPOSITED IN THE MACROPORES AND AT THE OUTSIDE WALL OF THE FIBERS. THE NOMINAL PORE SIZE OF THE MEMBRANE IS LESS THAN 30 KILODALTONS, AND ALLOWS IRON AND OTHER METALS TO PASS THROUGH. HOLLOW FIBER CARTRIDGES WITH THE IMMOBILIZED CHELATORS WILL THEN BE TESTED. USING AQUEOUS SOLUTIONS OF IRON, THE DEVICE WILL BE TESTED FOR KINETICS OF IRON REMOVAL AND IRON BINDING CAPACITY. USING BLOOD FROM HEMODIALYSIS PATIENTS HAVING IRON OVERLOAD, THE DEVICES WILL BE TESTED FOR KINETICS OF IRON REMOVAL. IDENTIFICATION OF THE SOURCES OF IRON 0 REMOVED WILL BE EXPLORED BY MEASURING IRON IN INDIVIDUAL SERUM FRACTIONS SEPARATED BY HPLC IN RECIRCULATING BLOOD. THESE PHASE I STUDIES WILL TEST THE FEASIBILITY OF THIS APPROACH TO IRON CHELATION AND IDENTIFY THE FINAL CHELATOR FOR THE PROTOTYPE TO BE DEVELOPED IN PHASE II.

Principal Investigator:

Ambrus, Clara M
Principal Investigator
7168838382

Business Contact:

1 r43 dk44394-01
Small Business Information at Submission:

Hemex, Inc
143 Windsor Avenue Buffalo, NY 14209

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No